Concentrazioni e Aquisizioni nel settore Scienze della vita
Chambers USA 2018, Client Reference
The strategy behind your business growth
Pushing boundaries and moving forward, you’re always looking for what’s next. Be ready to take advantage of merger and acquisition opportunities with a hand-selected team of legal advisors by your side. We’ll navigate the complex and highly regulated life sciences landscape and help prevent challenges from holding you back. So you can keep moving at the pace of innovation.
It’s what we do: we fuel missions and knock down barriers to successfully negotiate and close deals on behalf of life sciences businesses large and small, worldwide.
No matter what your growth looks like, our cross-border team can help with your collaborative transformations, including:
Traditional M&A deals
Strategic acquisition of distressed assets
Spin-offs, carve-outs and divestitures
Venture capital funding
Deals with universities, academic medical centers and research institutions
We offer comprehensive and holistic advice from an integrated team of Tier 1 health lawyers along with our deep bench of IP, regulatory, litigation, corporate, tax and employee benefits lawyers from more than 20 offices around the globe.
Siegfried Group on multiple transactions including the acquisition of significant parts of BASF’s pharmaceutical supply business and connected chemical-pharmaceutical production units and the acquisition of Hameln Pharmaceuticals and Hameln RDS, developers of sterile pharmaceutical products
Alliant Pharmaceuticals, Inc., with an approximately $100 million sale to Sciele Pharma, Inc.
Baird Capital Partners Asia and Frontage Laboratories in the acquisition of Advanced Biomedical Research, Inc., a clinical research company
Eli Lilly and Company with the $135 million acquisition of Pacific Biotech, Inc., a developer of diagnostic tests for detection of pregnancy, infectious diseases, strep throat and mononucleosis, pursuant to a reverse triangular merger
Baird Capital Partners and Baird Venture Partners in the acquisition of preferred stock of PharMEDium, a pharmaceutical company, with the initial preferred stock acquisition and, later, leveraged recapitalization
BioSource International, Inc., a publicly traded life sciences company, with the $130 million sale transaction to Invitrogen Corporation
Caprion Proteomics, a provider of proteomics-based service to the pharma and biotech industries, with the sale of a minority interest to Covance, Inc.
Gerresheimer, a global leader in the manufacture of glass and plastic packaging products for the pharmaceutical and healthcare industries, in the acquisition of all of the capital stock of Centor, the leading supplier of prescription drug packaging products in the United States and a portfolio company of Montagu Private Equity